Artificial intelligence in virtual screening: Models versus experiments

Drug Discov Today. 2022 Jul;27(7):1913-1923. doi: 10.1016/j.drudis.2022.05.013. Epub 2022 May 18.

Abstract

A typical drug discovery project involves identifying active compounds with significant binding potential for selected disease-specific targets. Experimental high-throughput screening (HTS) is a traditional approach to drug discovery, but is expensive and time-consuming when dealing with huge chemical libraries with billions of compounds. The search space can be narrowed down with the use of reliable computational screening approaches. In this review, we focus on various machine-learning (ML) and deep-learning (DL)-based scoring functions developed for solving classification and ranking problems in drug discovery. We highlight studies in which ML and DL models were successfully deployed to identify lead compounds for which the experimental validations are available from bioassay studies.

Keywords: Binding affinity; Binding assay studies; Chemical spaces; Computational drug discovery; Machine learning-based scoring; Scoring functions.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence*
  • Drug Discovery*
  • Machine Learning
  • Small Molecule Libraries

Substances

  • Small Molecule Libraries